Patents by Inventor Shimin Xu

Shimin Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090012299
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, A3, A4, B, R1, R2, R3, R4 and R5 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of P38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease, pain and other inflammatory disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Application
    Filed: May 6, 2008
    Publication date: January 8, 2009
    Applicant: Amgen Inc.
    Inventors: Liping Pettus, Andrew Tasker, Shimin Xu, Ryan Wurz
  • Patent number: 7435823
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: January 24, 2005
    Date of Patent: October 14, 2008
    Assignee: Amgen Inc.
    Inventors: Michele Potashman, Tae-Seong Kim, Steven Bellon, Shon Booker, Yuan Cheng, Joseph L. Kim, Andrew Tasker, Ning Xi, Shimin Xu, Jean-Christophe Harmange, George Borg, Matthew Weiss, Brian L. Hodous, Russell Graceffa, William H. Buckner, Craig E. Masse, Deborah Choquette, Matthew W. Martin, Julie Germain, Lucian V. DiPietro, Stuart C. Chaffee, Joseph J. Nunes, John L. Buchanan, Gregory J. Habgood, David C. McGowan, Douglas A. Whittington, Daniel La, Vinod F. Patel
  • Publication number: 20080200464
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: December 19, 2007
    Publication date: August 21, 2008
    Applicant: Amgen Inc.
    Inventors: Steven Bellon, Shon Booker, Noel D'Angelo, Julie Germain, Jean-Christophe Harmange, Tae-Seong Kim, Matthew Lee, Longbin Liu, Mark H. Norman, Elizabeth Rainbeau, Ning Xi, Shimin Xu
  • Publication number: 20080119468
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Application
    Filed: September 4, 2007
    Publication date: May 22, 2008
    Applicant: Amgen Inc.
    Inventors: Andrew Tasker, Dawei Zhang, Liping H. Pettus, Rob M. Rzasa, Kelvin K.C. Sham, Shimin Xu, Partha Chakrabarti
  • Publication number: 20070265248
    Abstract: Selected substituted piperazine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: April 27, 2005
    Publication date: November 15, 2007
    Applicant: Amgen Inc.
    Inventors: Christopher Fotsch, Premilla Arasasingham, Yunxin Bo, Ning Chen, Martin Goldberg, Nianhe Han, Feng-Yin Hsieh, Michael Kelly, Qingyian Liu, Mark Norman, Duncan Smith, Markian Stec, Nuria Tamayo, Ning Xi, Shimin Xu, Elizabeth Doherty
  • Patent number: 7265138
    Abstract: Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, d
    Type: Grant
    Filed: February 9, 2004
    Date of Patent: September 4, 2007
    Assignee: Amgen Inc.
    Inventors: Elizabeth M. Doherty, Christopher H. Fotsch, Nianhe Han, Randall W. Hungate, Qingyian Liu, Mark H. Norman, Ning Xi, Shimin Xu
  • Publication number: 20070142381
    Abstract: The compounds of the invention are represented by the following general structure or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: January 30, 2007
    Publication date: June 21, 2007
    Inventors: Michael Kelly, Shimin Xu, Ning Xi, Philip Miller, John Kincaid, Chiara Ghiron, Thomas Coulter
  • Patent number: 7196102
    Abstract: The compounds of the invention are represented by the following general structure or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: March 27, 2007
    Assignee: Amgen Inc.
    Inventors: Michael G. Kelly, Shimin Xu, Ning Xi, Philip Miller, John F. Kincaid, Chiara Ghiron, Thomas Coulter
  • Publication number: 20070054916
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I wherein A1, A2, A3, B, R1, R2, R3 and R4 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention.
    Type: Application
    Filed: September 30, 2005
    Publication date: March 8, 2007
    Inventors: Vinod Patel, Joseph Kim, Stephanie Geuns-Meyer, Stuart Chaffee, Victor Cee, Brian Hodous, Steven Bellon, Jean-Christophe Harmange, Philip Olivieri, Maya Thaman, Erin DiMauro, John Buchanan, David McGowan, Brian Albrecht, Holly Deak, Jean Bemis, Ryan White, Matthew Martin, Gregory Habgood, Paul Tempest, Craig Masse, William Buckner, Bradley Herberich, Russell Graceffa, Dawei Zhang, Shimin Xu, Kelvin Sham, Robert Rzasa, James Falsey, Partha Chakrabarti, Guo-Qiang Cao, Susan Tomlinson, Liping Pettus, Adrian Smith, Nick Paras, Gang Liu, Frenel DeMorin, Andrew Tasker, Anthony Reed
  • Patent number: 7176322
    Abstract: The compounds of the invention are represented by the following general structure or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: May 22, 2003
    Date of Patent: February 13, 2007
    Assignee: Amgen Inc.
    Inventors: Michael G. Kelly, Shimin Xu, Ning Xi, Robert Townsend, David Semin, Chiara Ghiron, Thomas Coulter
  • Publication number: 20060241115
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: January 24, 2005
    Publication date: October 26, 2006
    Inventors: Michele Potashman, Tae-Seong Kim, Steven Bellon, Shon Booker, Yuan Cheng, Joseph Kim, Andrew Tasker, Ning Xi, Shimin Xu, Jean-Christophe Harmange, George Borg, Matthew Weiss, Brian Hodous, Russell Graceffa, William Buckner, Craig Masse, Deborah Choquette, Matthew Martin, Julie Germain, Lucian DiPietro, Stuart Chaffee, Joseph Nunes, John Buchanan, Gregory Habgood, David McGowan, Douglas Whittington
  • Patent number: 7115607
    Abstract: Selected substituted piperazine compounds of Formula I are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: October 3, 2006
    Assignee: Amgen Inc.
    Inventors: Christopher H. Fotsch, Premilla Arasasingham, Yunxin Bo, Ning Chen, Martin H. Goldberg, Nianhe Han, Feng-Yin Hsieh, Michael G. Kelly, Qingyian Liu, Mark H. Norman, Duncan M. Smith, Markian Stec, Nuria Tamayo, Ning Xi, Shimin Xu
  • Patent number: 7105682
    Abstract: Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: January 10, 2002
    Date of Patent: September 12, 2006
    Assignee: Amgen Inc.
    Inventors: Guoqing Chen, Jeffrey Adams, Jean Bemis, Lucian Di Pietro, Celia Dominguez, Daniel Elbaum, Julie Germain, Qi Huang, Joseph L. Kim, Xiaohu Ouyang, Vinod F. Patel, Leon M. Smith, Andrew Tasker, Ning Xi, Shimin Xu, Chester Chenguang Yuan, Michael Croghan, Tae-Seong Kim
  • Publication number: 20060199817
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Application
    Filed: March 2, 2006
    Publication date: September 7, 2006
    Applicant: Amgen Inc.
    Inventors: Andrew Tasker, Dawei Zhang, Guo-Qiang Cao, Partha Chakrabarti, James Falsey, Bradley Herberich, Randall Hungate, Liping Pettus, Anthony Reed, Robert Rzasa, Kelvin Sham, Maya Thaman, Shimin Xu
  • Patent number: 7101868
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: April 12, 2004
    Date of Patent: September 5, 2006
    Assignee: Amgen Inc.
    Inventors: Daniel Elbaum, Benny C. Askew, Jr., Shon Booker, Julie Germain, Gregory J. Habgood, Michael Handley, Tae-Seong Kim, Aiwen Li, Nobuko Nishimura, Vinod F. Patel, Chester Chenguang Yuan, Joseph L. Kim, Guolin Cai, Guoqing Chen, Michael Croghan, Lucian V. Di Pietro, Celia Dominguez, Qi Huang, Leon M. Smith, II, Andrew Tasker, Ning Xi, Shimin Xu
  • Publication number: 20060194848
    Abstract: Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: May 2, 2006
    Publication date: August 31, 2006
    Inventors: Guoqing Chen, Jeffrey Adams, Jean Bemis, Lucian Di Pietro, Celia Dominguez, Daniel Elbaum, Julie Germain, Qi Huang, Joseph Kim, Xiaohu Ouyang, Vinod Patel, Leon Smith, Andrew Tasker, Ning Xi, Shimin Xu, Chester Yuan, Michael Croghan, Tae-Seong Kim
  • Publication number: 20060040956
    Abstract: Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: September 23, 2005
    Publication date: February 23, 2006
    Inventors: Guoqing Chen, Jeffrey Adams, Jean Bemis, Shon Booker, Guolin Cai, Lucian Di Pietro, Celia Dominguez, Daniel Elbaum, Julie Germain, Stephanie Geuns-Meyer, Michael Handley, Qi Huang, Joseph Kim, Tae-Seong Kim, Alexander Kiselyov, Xiaohu Ouyang, Vinod Patel, Leon Smith, Markian Stec, Andrew Tasker, Ning Xi, Shimin Xu, Chester Yuan, Michael Croghan
  • Patent number: 6995162
    Abstract: Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: January 10, 2002
    Date of Patent: February 7, 2006
    Assignee: Amgen Inc.
    Inventors: Guoqing Chen, Jeffrey Adams, Jean Bemis, Shon Booker, Guolin Cai, Lucian Di Pietro, Celia Dominguez, Daniel Elbaum, Julie Germain, Stephanie Geuns-Meyer, Michael Handley, Qi Huang, Joseph L. Kim, Tae-Seong Kim, Alexander Kiselyov, Xiaohu Ouyang, Vinod F. Patel, Leon M. Smith, Markian Stec, Andrew Tasker, Ning Xi, Shimin Xu, Chester Chenguang Yuan, Michael Croghan
  • Patent number: 6977264
    Abstract: Selected substituted piperidine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: December 20, 2005
    Assignee: Amgen Inc.
    Inventors: Christopher H. Fotsch, Michael Croghan, Elizabeth M. Doherty, Michael G. Kelly, Mark H. Norman, Duncan M. Smith, Nuria Tamayo, Ning Xi, Shimin Xu
  • Publication number: 20050245547
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: January 24, 2005
    Publication date: November 3, 2005
    Inventors: Tae-Seong Kim, Jean-Christophe Harmange, David Bauer, Shon Booker, Yuan Cheng, Shimin Xu, Ning Xi, Joseph Kim, Andrew Tasker